Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&amp;M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ohanian M, Cable CC, Halka KK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/65e2b59bd0324ba0b6de9db31e3d079a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:65e2b59bd0324ba0b6de9db31e3d079a
record_format	dspace
spelling	oai:doaj.org-article:65e2b59bd0324ba0b6de9db31e3d079a2021-12-02T05:25:17ZEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome1179-1438https://doaj.org/article/65e2b59bd0324ba0b6de9db31e3d079a2011-05-01T00:00:00Zhttp://www.dovepress.com/eculizumab-safely-reverses-neurologic-impairment-and-eliminates-need-f-a7516https://doaj.org/toc/1179-1438Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&amp;M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric microthrombi. Due to mental and respiratory decline, she remained intubated. Continuous venovenous hemodialysis was initiated. Renal failure, neurologic changes, hemolysis, thrombotic microangiopathy, and low complement levels all suggested atypical hemolytic uremic syndrome. Eculizumab 900 mg was administered intravenously on hospital day 6 and continued weekly for four doses followed by maintenance therapy. She recovered neurologically and renally after the third dose, and hematologically by the sixth dose. Her recovery has been sustained on long-term eculizumab treatment. In severe atypical hemolytic uremic syndrome, eculizumab safely reverses neurologic impairment and eliminates the need for dialysis. The optimal duration of treatment with eculizumab remains to be determined.Keywords: eculizumab, thrombotic microangiopathy, atypical hemolytic uremic syndromeOhanian MCable CCHalka KKDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2011, Iss default, Pp 5-12 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Ohanian M Cable CC Halka KK Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
description	Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&amp;M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric microthrombi. Due to mental and respiratory decline, she remained intubated. Continuous venovenous hemodialysis was initiated. Renal failure, neurologic changes, hemolysis, thrombotic microangiopathy, and low complement levels all suggested atypical hemolytic uremic syndrome. Eculizumab 900 mg was administered intravenously on hospital day 6 and continued weekly for four doses followed by maintenance therapy. She recovered neurologically and renally after the third dose, and hematologically by the sixth dose. Her recovery has been sustained on long-term eculizumab treatment. In severe atypical hemolytic uremic syndrome, eculizumab safely reverses neurologic impairment and eliminates the need for dialysis. The optimal duration of treatment with eculizumab remains to be determined.Keywords: eculizumab, thrombotic microangiopathy, atypical hemolytic uremic syndrome
format	article
author	Ohanian M Cable CC Halka KK
author_facet	Ohanian M Cable CC Halka KK
author_sort	Ohanian M
title	Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
title_short	Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
title_full	Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
title_fullStr	Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
title_full_unstemmed	Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
title_sort	eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/65e2b59bd0324ba0b6de9db31e3d079a
work_keys_str_mv	AT ohanianm eculizumabsafelyreversesneurologicimpairmentandeliminatesneedfordialysisinsevereatypicalhemolyticuremicsyndrome AT cablecc eculizumabsafelyreversesneurologicimpairmentandeliminatesneedfordialysisinsevereatypicalhemolyticuremicsyndrome AT halkakk eculizumabsafelyreversesneurologicimpairmentandeliminatesneedfordialysisinsevereatypicalhemolyticuremicsyndrome
_version_	1718400414827675648

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Ejemplares similares